Jove
Visualize
Contact Us

Related Experiment Videos

Leukotriene receptor antagonist therapy.

O J Dempsey1

  • 1Asthma and Allergy Research Group, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK.

Postgraduate Medical Journal
|November 21, 2000
PubMed
Summary

Leukotriene receptor antagonists (LTRA) offer new asthma treatment options. These oral medications provide both bronchodilator and anti-inflammatory benefits, marking a significant advancement in asthma pharmacotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electronic cigarettes: a brief update.

The journal of the Royal College of Physicians of Edinburgh·2018
Same author

Metastatic thymoma, placenta praevia and two successful pregnancies: an obstetric challenge.

European journal of obstetrics, gynecology, and reproductive biology·2012
Same author

Neurosarcoidosis-related intracranial haemorrhage: three new cases and a systematic review of the literature.

European journal of neurology·2012
Same author

A persisting puzzling pneumonia in a young man.

BMJ (Clinical research ed.)·2012
Same author

Incomplete Carney triad--a review of two cases.

QJM : monthly journal of the Association of Physicians·2009
Same author

Idiopathic pulmonary fibrosis: an update.

QJM : monthly journal of the Association of Physicians·2006
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Discovery

Background:

  • Asthma is a chronic respiratory disease characterized by airway inflammation and bronchoconstriction.
  • Current asthma management involves various therapeutic classes, including inhaled corticosteroids and bronchodilators.
  • There is an ongoing need for novel pharmacotherapies with improved efficacy and safety profiles.

Purpose of the Study:

  • To introduce Leukotriene Receptor Antagonists (LTRA) as a new class of oral asthma medications.
  • To describe the dual mechanism of action of LTRA, encompassing bronchodilator and anti-inflammatory effects.
  • To highlight the potential role of LTRA in the evolving landscape of asthma management.

Main Methods:

  • This section is not detailed in the provided abstract.
  • The abstract focuses on the drug class and its effects rather than specific study methodologies.
  • Further details on clinical trials or in vitro studies would be required to populate this section.

Main Results:

  • LTRA are available in tablet form, offering a convenient oral administration route.
  • These agents exhibit a unique mechanism of action, combining bronchodilator and anti-inflammatory properties.
  • The clinical efficacy and optimal positioning of LTRA within asthma treatment guidelines are subjects of ongoing review.

Conclusions:

  • Leukotriene Receptor Antagonists represent a significant advancement in asthma pharmacotherapy.
  • Their combined bronchodilator and anti-inflammatory effects offer a novel therapeutic approach.
  • While their definitive role is under evaluation, LTRA are an important addition to the asthma treatment armamentarium.

Related Experiment Videos